Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients with Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae

Clinical Infectious Diseases

Volumn 68, Issue 3, 2019, Pages 355-364

  Tumbarello, Mario ^a   Trecarichi, Enrico Maria ^a   Corona, Alberto ^b   De Rosa, Francesco Giuseppe ^c   Bassetti, Matteo ^d   Mussini, Cristina ^e   Menichetti, Francesco ^f   Viscoli, Claudio ^g   Campoli, Caterina ^h   Venditti, Mario ⁱ   De Gasperi, Andrea ^j   Mularoni, Alessandra ^k   Tascini, Carlo ^l   Parruti, Giustino ^m   Pallotto, Carlo ⁿ   Sica, Simona ^o   Concia, Ercole ^p   Cultrera, Rosario ^q   De Pascale, Gennaro ^a   Capone, Alessandro ^r   Antinori, Spinello ^s   Corcione, Silvia ^c   Righi, Elda ^d   Losito, Angela Raffaella ^a   Digaetano, Margherita ^e   Amadori, Francesco ^f   Giacobbe, Daniele Roberto ^g   Ceccarelli, Giancarlo ⁱ   Mazza, Ernestina ^j   Raffaelli, Francesca ^a   Spanu, Teresa ^a   Cauda, Roberto ^a   Viale, Pierluigi ^h   more..

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d S Maria Hospital   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f CISANELLO HOSPITAL   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ POLICLINICO UMBERTO I   (Italy)

^j OSPEDALE NIGUARDA CA GRANDA   (Italy)

^k MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^l AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^m Azienda Unita Sanitaria Locale Pescara   (Italy)

ⁿ UNIVERSITY OF PERUGIA   (Italy)

^o CATHOLIC UNIVERSITY   (Italy)

^p UNIVERSITY OF VERONA   (Italy)

^q UNIVERSITY OF FERRARA   (Italy)

^r NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^s UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

carbapenemases; ceftazidime avibactam; KPC producing Klebsiella pneumoniae.

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; CARBAPENEMASE; COLISTIN; FOSFOMYCIN; GENTAMICIN; TIGECYCLINE; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR; CEFTAZIDIME;

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MORTALITY; MULTICENTER STUDY; NEUTROPENIA; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SEPTIC SHOCK; TREATMENT OUTCOME; AGED; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG COMBINATION; ISOLATION AND PURIFICATION; ITALY; KLEBSIELLA INFECTION; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PROCEDURES; SURVIVAL ANALYSIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEFTAZIDIME; DRUG COMBINATIONS; FEMALE; HUMANS; ITALY; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85056438290     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy492     Document Type: Article

References (37)

1. US Food and Drug Administration (FDA). FDA approves new antibacterial drug Avycaz. FDA news release. Silver Spring, MD: FDA, 2015. Available at: https://www.accessdata.fda.gov/drugsatfda-docs/appletter/2015/206494Orig1s000ltr. pdf. Accessed 19 March 2018.
2. European Medicines Agency (EMA). European public assessment report (EPAR) for Zavicefta. 2016. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/004027/WC500210237.pdf. Accessed 19 March 2018.
3. Trecarichi EM, Tumbarello M. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence 2017; 8:470-84.
4. Viale P, Giannella M, Lewis R, Trecarichi EM, Petrosillo N, Tumbarello M. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther 2013; 11:1053-63.
5. Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev 2018; 31:2.
6. Bassetti M, Giacobbe DR, Giamarellou H, et al; Critically Ill Patients Study Group of the European Society of Clinical Microbiology and Infectious Disease (ESCMID); Hellenic Society of Chemotherapy (HSC) and Societa Italiana di Terapia Antinfettiva (SITA). Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect 2018; 24:133-44.
7. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014; 20:862-72.
8. Bonomo RA, Burd EM, Conly J, et al. Carbapenemase-producing organisms: a global scourge. Clin Infect Dis 2018; 66:1290-7.
9. Guh AY, Bulens SN, Mu Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012-2013. JAMA 2015; 314:1479-87.
10. Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill 2015; 20:45.
11. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 2017; 8:460-9.
12. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943-50.
13. Tumbarello M, Trecarichi EM, Tumietto F, et al. Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2014; 58:3514-20.
14. Giannella M, Trecarichi EM, De Rosa FG, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect 2014; 20:1357-62.
15. Giacobbe DR, Del Bono V, Trecarichi EM, et al; ISGRI-SITA (Italian Study Group on Resistant Infections of the Societa Italiana Terapia Antinfettiva). Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect 2015; 21:1106.e1-8.
16. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation -lactam/-lactamase inhibitor combinations. Clin Infect Dis 2016; 63:234-41.
17. Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis 2018; 18:285-95.
18. Vazquez JA, Gonzalez Patzan LD, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012; 28:1921-31.
19. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 2013; 68:1183-92.
20. Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 2016; 62:1380-9.
21. Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 2016; 63:754-62.
22. Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 2017; 61:2.
23. Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016; 63:1615-8.
24. Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother 2018. In press.
25. King M, Heil E, Kuriakose S, et al. Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother 2017; 61:e00449-17.
26. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 2017; 61:8.
27. van Duin D, Lok JJ, Earley M, et al; Antibacterial Resistance Leadership Group. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2018; 66:163-71.
28. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 2004; 140:26-32.
29. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017; 43:304-77.
30. European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 2.0, July 2017. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Resistance-mechanisms/EUCAST-detection-of-resistance-mechanisms-170711.pdf. Accessed 25 June 2018.
31. Giannella M, Trecarichi EM, Giacobbe DR, et al; Italian Study Group on Resistant Infections of the Societa Italiana Terapia Antinfettiva (ISGRI-SITA). Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents 2018; 51:244-8.
32. Gutierrez-Gutierrez B, Salamanca E, de Cueto M, et al; REIPI/ESGBIS/INCREMENT Investigators. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 2017; 17:726-34.
33. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58:2322-8.
34. Tumbarello M, Trecarichi EM, De Rosa FG, et al; ISGRI-SITA (Italian Study Group on Resistant Infections of the Societa Italiana Terapia Antinfettiva). Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015; 70:2133-43.
35. European Centre for Disease Prevention and Control (ECDC). Summary of the latest data on antibiotic resistance in EU: 2016. Available at: https://ecdc.europa. eu/en/publications-data/summary-latest-data-antibiotic-resistance-eu-2016. Accessed 19 March 2018.
36. Rojas LJ, Salim M, Cober E, et al; Antibacterial Resistance Leadership Group. Colistin resistance in carbapenem-resistant Klebsiella pneumoniae: laboratory detection and impact on mortality. Clin Infect Dis 2017; 64:711-8.
37. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913-20.